Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Sexual Dysfunction Inadequately Reported In Hair Loss Drug Trials For Men
Clinical Breakthroughs

Sexual Dysfunction Inadequately Reported In Hair Loss Drug Trials For Men

By Marla PaulApr 1, 2015
Share
Facebook Twitter Email
Steven Belknap, ’82 MD, research assistant professor in Dermatology and Medicine-General Internal Medicine and Geriatrics, was lead author on the study that examined the safety of finasteride, a male hair-loss treatment. 

 

Published reports of clinical trials provide insufficient information to adequately establish the safety of finasteride for treatment of hair loss in men, according to a new Northwestern Medicine study to be published April 1 in JAMA Dermatology. This study is the first meta-analysis of the quality of safety reporting in clinical trials of finasteride for treatment of male hair loss.

Finasteride blocks 5α-reductase in the scalp and male reproductive organs, inhibiting the conversion of the male hormone testosterone to its more potent form, 5α-dihydrotestosterone (5α- DHT). Men who take finasteride experience a 70 percent reduction in the amount of 5α-DHT in their blood.

Not one of the 34 published clinical trial reports provided adequate information about the severity, frequency or reversibility of sexual adverse effects. (Adequate quality of adverse event reporting requires using an explicit toxicity scale to grade adverse event severity and reported numbers and/or rates of occurrence for each specific type of adverse event per study arm.)

The published clinical trial reports did not answer the key questions doctors and patients want to know:

1) How safe is finasteride? Specifically, what is the risk that a man taking finasteride will develop sexual dysfunction?

2) How severe is finasteride-associated sexual dysfunction when it happens to a man?

3) If a man gets sexual dysfunction while taking finasteride, will sexual function return to normal when the drug is stopped? What is the risk of persistent sexual dysfunction associated with taking finasteride?

Finasteride was originally developed to treat enlarged prostate (prostatic hyperplasia) in older men. Men who take the drug for male pattern hair loss are typically younger and take a dose of finasteride that is about one-fifth the dose used for prostatic hyperplasia.

“People who take or prescribe the drug assume it’s safe, but there is insufficient information to make that judgment,” said lead study author Steven Belknap, ’82 MD, research assistant professor in Dermatology and Medicine-General Internal Medicine and Geriatrics.

“Our findings raise several questions,” Dr. Belknap said. “Why do the published reports of these 34 clinical trials not provide adequate information about the severity and frequency of sexual toxicity? Was this information obtained but then not included in published articles? Or, were these clinical trials performed in a way that simply didn’t capture this essential information? And most importantly, is the risk to benefit ratio of finasteride acceptable?”

The study is a report from the RADAR (Research on Adverse Drug Events and Reports) project at Northwestern’s Feinberg School. The RADAR study points to a larger problem in the way clinical trials are performed and analyzed in meta-analyses.

“Typically, there is more focus on the desirable effects of the drug being studied compared to the toxic effects,” Dr. Belknap said.

Among other key findings of the paper:

Of 5,704 men in the Northwestern Medicine clinical data repository who were treated for male pattern baldness with finasteride, only 31 percent would meet inclusion criteria for the pivotal trials referenced in the manufacturer’s “Full Prescribing Information.”

Thus, the available information from clinical trials does not apply to most of these men in Northwestern’s study population who took finasteride for male pattern baldness. For example, some men with hair loss who are taking finasteride have diabetes mellitus, high blood pressure or are taking other drugs such as diuretics or antidepressants that also increase the risk of sexual dysfunction.

Duration of drug safety evaluation was limited to one year or less for 26 of 34 trials (76 percent.) But 33 percent of men in the Northwestern clinical data repository took finasteride for more than one year.

Other Northwestern authors on the study are senior author Dennis West, PhD, Vincent W. Foglia Family Research Professor of Dermatology; Robert Brannigan, ’92 MD, professor in Urology; Beatrice Nardone, MD, PhD, research assistant professor in Dermatology; Imran Aslam; Tina Kiguradze; William Temps and John Cashy.

The study was funded by 5R01CA102713-04 and 1R01 CA125077-01A1 from the National Cancer Institute of the National Institutes of Health. Additional funding was provided by the Post-Finasteride Syndrome Foundation.

Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Comments are closed.

Latest News

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.